Physician profile
David Robinson
NPI 1225363450
$3,509.71
in general payments reported to CMS, 2019-2025
22 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2022: $778 · 2023: $501 · 2024: $657 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $605.10 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $414.31 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Optinose US, INC. | $294.68 | 2021-2025 | |
| Csl Behring | $265.70 | 2022-2025 | Andembry, Haegarda, Hizentra |
| Amgen INC. | $265.47 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $263.56 | 2025 | |
| Genzyme Corporation | $235.43 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.51 | 2021-2024 | Hyqvia, Cuvitru, Eohilia |
| Teva Pharmaceuticals USA, INC. | $198.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $110.61 | 2022-2023 | Dupixent |
| Blueprint Medicines Corporation | $100.74 | 2023-2025 | Ayvakit |
| Pfizer INC. | $90.79 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $86.29 | 2025 | Neffy |
| Octapharma USA, INC. | $81.64 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga, Cutaquig |
| Kaleo, INC. | $64.31 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.71 | 2021-2023 | |
| Pharming Healthcare, INC. | $36.66 | 2021-2025 | Ruconest |
| Lilly USA, LLC | $22.15 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $21.35 | 2025 | Dawnzera |
| Paratek Pharmaceuticals, INC. | $15.01 | 2025 | Xhance |
| Alk-Abello, INC | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.